Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

LIPI Score (Lung Immune)

The Lung Immune Prognostic Index (LIPI) stratifies outcomes in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) treated with immune checkpoint inhibitors (PD-1/PD-L1 inhibitors).

Evidence-based context for fast calculator use

Purpose:
LIPI Score stratifies metastatic NSCLC patients by dNLR and LDH to predict immunotherapy response and guide checkpoint inhibitor decisions.
Population:
patients undergoing lung cancer immunotherapy or prognostic assessment
Factors:
dNLR > 3?, LDH > Upper Limit of Normal?
Reference:
Mezquita L, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018;4(3):351-357.
HomeLIPI Score (Lung Immune)
Pin your most used calculators here by clicking the star in the dropdown.

LIPI Score (Lung Immune)

Clinical Context & Background

The Lung Immune Prognostic Index (LIPI) stratifies outcomes in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) treated with immune checkpoint inhibitors (PD-1/PD-L1 inhibitors). It uses derived NLR (dNLR) and LDH.
Primary Source EvidenceMezquita L, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018;4(3):351-357.
Formula Logic
Risk factors: dNLR > 3 and LDH > ULN.

Reference Data

Risk GroupFactorsOutcomes
Good0 factorsBest PFS and OS
Intermediate1 factorIntermediate outcomes
Poor2 factorsWorst PFS and OS

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use LIPI Score (Lung Immune) when lIPI Score stratifies metastatic NSCLC patients by dNLR and LDH to predict immunotherapy response and guide checkpoint inhibitor decisions.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Good through Poor.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Integrate the result with histology, molecular profile, stage, treatment line, imaging, and performance status.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not transfer an immunotherapy or laboratory prognostic score to an unvalidated treatment setting.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing lung cancer immunotherapy or prognostic assessment

How to apply this result

For a representative case, verify dNLR > 3?, LDH > Upper Limit of Normal?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Lung Cancer & IO hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

GRIm ScoreLung-RADS™ v2022

Frequently Asked Questions

When should LIPI Score (Lung Immune) be used?

Use it for patients undergoing lung cancer immunotherapy or prognostic assessment when all required inputs and the intended clinical setting are confirmed.

Can LIPI Score (Lung Immune) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.